Resharing a clip from $CERo's Director Brandon Cieniewicz discussing how the team is advancing a novel approach to engineered T cell therapy.
Learn about the design behind CER-1236 and its potential to target cancer cells.
#ICYMI: In Drug Development & Delivery, Chris Ehrlich shares how CER-T cells are designed to recognize & “eat” cancer cells, with early progress from a Phase 1/1b #AML trial.
Initial patients have been dosed at sites incl. @UTMDAnderson.
Read more: https://t.co/UiIEZpZFZv
$CERo
In a new @pulse2news interview, $CERo's CEO, Chris Ehrlich, discusses the Company's innovative CER-T cell therapy platform, the progress of the ongoing CERTAIN-T Phase 1 trial, and CERo's vision for advancing next-generation immunotherapies.
Read the full interview: https://t.co/o0rjY1cvFE
This #NationalCancerSurvivorMonth, we recognize the strength of cancer survivors and all those who support them throughout their journeys.
At $CERo, their journeys continue to inspire our mission to advance engineered T cell therapies for difficult-to-treat cancers.
Following Cohort 2 completion, #CERoTherapeutics is advancing CER-1236 into Cohort 3.
As CEO, Chris Ehrlich noted, $CERo looks ahead to further clinical updates.
Read more: https://t.co/9iHyazuHlb
#MDS#MF#ClinicalTrials
$CERo's CMO, Robert Sikorski, shared insights with @TrialsArena on collaborating with the FDA and advancing CERo’s novel cell therapy program.
He also highlighted the dedication of the FDA’s technical staff in supporting clinical development.
Read more: https://t.co/jXn7KBeAFk